CRISPR Therapeutics (NASDAQ: CRSP) has had a volatile performance over the past five years. While its stock is up more than ...

CRISPR Therapeutics AG (CRSP) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's ...

According to Benzinga Pro, CRISPR Therapeutics AG's peer group average for short interest as a percentage of float is 14.28%, ...

CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

As of Wednesday, December 17, EUDA Health Holdings Limited’s EUDA share price has surged by 5.42%, which has investors ...

On the one hand, these stocks tend to have explosive growth potential, much more so than most of their larger counterparts.

Let's consider these excellent candidates: CRISPR Therapeutics (NASDAQ: CRSP) and Vertex Pharmaceuticals (NASDAQ: VRTX), two ...

Cathie Wood aims to identify innovators and invest in them early in their stories. Wood has been regularly adding to her position in this stock, and it’s one of her top holdings. 10 stocks we like ...

If you have been wondering whether CRISPR Therapeutics at around $57 a share is a bargain or a bubble, you are not alone. This stock sits at the crossroads of high science and high expectations. The ...

The following players span a variety of industries, so if you pick up more than one, you may gain in diversification.

CRISPR Therapeutics recently drew attention as updates highlighted progress in its gene-editing pipeline, including early-stage studies of CTX310, an in vivo therapy designed to lower LDL cholesterol ...